Editas Medicine (NasdaqGS:EDIT) Stock Price & Quote Analysis

EDIT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

EDIT Stock Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

Rewards

Revenue is forecast to grow 48.27% per year

Risk Analysis

Earnings are forecast to decline by an average of 2.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Editas Medicine, Inc. Competitors

Coherus BioSciences

NasdaqGM:CHRS

US$656.8m

VectivBio Holding

NasdaqGS:VECT

US$517.5m

Sangamo Therapeutics

NasdaqGS:SGMO

US$583.4m

Vanda Pharmaceuticals

NasdaqGM:VNDA

US$620.2m

Price History & Performance

Summary of all time highs, changes and price drops for Editas Medicine
Historical stock prices
Current Share Price	US$10.06
52 Week High	US$32.37
52 Week Low	US$9.59
Beta	1.96
1 Month Change	-21.10%
3 Month Change	-32.17%
1 Year Change	-66.50%
3 Year Change	-66.90%
5 Year Change	-60.98%
Change since IPO	-44.73%

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Recent updates

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17

Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Sep 07

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Aug 12

We're Not Very Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Apr 29

Chairman James Mullen Just Bought 250% More Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Mar 05

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 11%

Feb 27

Could The Editas Medicine, Inc. (NASDAQ:EDIT) Ownership Structure Tell Us Something Useful?

Feb 12

What Does The Future Hold For Editas Medicine, Inc. (NASDAQ:EDIT)? These Analysts Have Been Cutting Their Estimates

Jan 21

This Insider Has Just Sold Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Jan 15

Here's Why We're Not At All Concerned With Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Jan 01

Did Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Sell Shares?

Dec 06

Shareholder Returns

	EDIT	US Biotechs	US Market
7D	-3.0%	2.7%	1.4%
1Y	-66.5%	-10.3%	-16.1%

Return vs Industry: EDIT underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: EDIT underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is EDIT's price volatile compared to industry and market?
EDIT volatility
EDIT Average Weekly Movement	11.4%
Biotechs Industry Average Movement	11.2%
Market Average Movement	7.4%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.3%

Stable Share Price: EDIT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: EDIT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2013	264	Gilmore O’Neill	https://www.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

Editas Medicine, Inc. Fundamentals Summary

How do Editas Medicine's earnings and revenue compare to its market cap?
EDIT fundamental statistics
Market Cap	US$676.63m
Earnings (TTM)	-US$201.13m
Revenue (TTM)	US$25.65m

26.4x

P/S Ratio

-3.4x

P/E Ratio

Is EDIT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
EDIT income statement (TTM)
Revenue	US$25.65m
Cost of Revenue	US$160.51m
Gross Profit	-US$134.87m
Other Expenses	US$66.26m
Earnings	-US$201.13m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.99
Gross Margin	-525.90%
Net Profit Margin	-784.29%
Debt/Equity Ratio	0%

How did EDIT perform over the long term?

See historical performance and comparison

EDIT Stock Overview

Rewards

Risk Analysis

Editas Medicine, Inc. Competitors

NasdaqGM:CHRS

US$656.8m

NasdaqGS:VECT

US$517.5m

NasdaqGS:SGMO

US$583.4m

NasdaqGM:VNDA

US$620.2m

Price History & Performance

Recent News & Updates

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Recent updates

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates fall by 12%

Price target decreased to US$31.21

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Executive VP & Chief Business Officer notifies of intention to sell stock

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$37.23

Consensus revenue estimates increase by 15%

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Editas Medicine, Inc. Terminates Lisa Michaels as Chief Medical Officer

Chairman recently sold US$492k worth of stock

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Executive VP & Chief Medical Officer recently sold US$60k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.13 profit in 3Q 2020)

Chairman recently sold US$525k worth of stock

Chairman notifies of intention to sell stock

Price target increased to US$54.77

Editas Medicine, Inc. Announces Initial Clinical Data from Clinical Trial of EDIT-101 for an Oral Presentation at the XIXth International Symposium on Retinal Degeneration

Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Editas Medicine, Inc. Presents Data on New Sleek Gene Editing Technology

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

CFO, Principal Accounting Officer exercised options and sold US$73k worth of stock

Consensus forecasts updated

Price target increased to US$47.92

Second quarter 2021 earnings released: US$0.81 loss per share (vs US$0.43 loss in 2Q 2020)

CFO, Principal Accounting Officer notifies of intention to sell stock

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

Consensus forecasts updated

First quarter 2021 earnings released: US$0.86 loss per share (vs US$0.69 loss in 1Q 2020)

Price target decreased to US$48.33

We're Not Very Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Price target decreased to US$47.67

Chairman recently bought US$1.2m worth of stock

Chairman James Mullen Just Bought 250% More Shares In Editas Medicine, Inc. (NASDAQ:EDIT)

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 11%

Full year 2020 earnings released: US$1.98 loss per share (vs US$2.68 loss in FY 2019)

Revenue and earnings beat expectations

Editas Medicine Announces Update on Clinical Updates

Editas Medicine, Inc. Appoints James C. Mullen as President